| cm214_pfs {survAH} | R Documentation |
Sample Reconstructed Data of CheckMate214 Study
Description
The progression-free survival data reconstructed from the publication of the CheckMate214 study.
Usage
data(cm214_pfs)
Format
A dataset containing 3 columns:
- time
the time-to-event variable (the time unit is month)
- status
the event indicator (1=event, 0=censor)
- arm
the treatment indicator (1=treatment, 0=control)
Details
This is a reconstructed patient-level data from the results reported by Motzer et al.(2018) <doi:10.1056/NEJMoa1712126>. The data consists of 847 patients with previously untreated clear-cell advanced renal-cell carcinoma; 425 for the nivolumab plus ipilimumab group (treatment) and 422 for the sunitinib group (control).
Source
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine. 2018;378(14):1277–1290. <doi:10.1056/NEJMoa1712126> Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. <doi:10.1186/1471-2288-12-9>